

November 23, 2020

**BSE** Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531 The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR

Dear Madam/Sir,

**Sub:** Press Release

Please find attached Press Release issued by the Company titled:

"Strides receives USFDA approval for Prednisone Tablets"

Thanks & Regards,

For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary

Manjula R.

Encl. As above



# Strides receives USFDA approval for Prednisone Tablets

### To be marketed by Strides Pharma Inc. in the US market

**Bengaluru, November 23, 2020 –** Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for *Prednisone Tablets USP, 2.5 mg and 5 mg* from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Deltasone Tablets, 2.5 mg and 5 mg, of Pharmacia and Upjohn Co.

According to IQVIA MAT September 2020 data, the US market for Prednisone Tablets USP, 2.5 mg and 5 mg is approximately US\$ 30 Mn. The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 127 cumulative ANDA filings with USFDA of which 93 ANDAs have been approved and 34 are pending approval.

#### **About Prednisone Tablets**

Prednisone belongs to a class of drugs known as corticosteroids and is used as an anti-inflammatory or an immunosuppressant medication. It is used in treatment of different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.

## **About Strides**

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at <a href="https://www.strides.com">www.strides.com</a>

### For further information, please contact:

# <u>Strides</u>

#### **Badree Komandur**

Executive Director – Finance & Group CFO +91 80 6784 0747

## **Investor Relations:**

Sandeep Baid: +91 80 6784 0791 Email: Sandeep.baid@strides.com

### **Corporate Communication**

**Usha lyer:** +91 99874 44106 Email: <u>usha.iyer@strides.com</u>

### **PR Consultancy**

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

K Priya: +91 95354 25418 priya@fortunapr.com

## **Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,

Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,

. Bengaluru – 560 076